Literature DB >> 12019131

Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil.

Paula Prazeres Magalhães1, Dulciene Maria De Magalhães Queiroz, Daniela Vale Campos Barbosa, Gifone Aguiar Rocha, Edilberto Nogueira Mendes, Adriana Santos, Paulo Renato Valle Corrêa, Andreia Maria Camargos Rocha, Lúcia Martins Teixeira, Celso Affonso de Oliveira.   

Abstract

Helicobacter pylori resistance to metronidazole was detected in 107 (52.97%) of 202 strains. Twenty (9.85%) strains, 18 of them harboring 23S ribosomal DNA mutations, were resistant to clarithromycin. Metronidazole resistance was associated with female gender. Resistance to metronidazole and resistance to clarithromycin were associated. Increasing clarithromycin resistance rates were observed over time.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12019131      PMCID： PMC127243          DOI： 10.1128/AAC.46.6.2021-2023.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  PCR using 3'-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates.

Authors:  T Alarcón; D Domingo; N Prieto; M López-Brea
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 2.  Helicobacter pylori: its role in disease.

Authors:  M J Blaser
Journal:  Clin Infect Dis       Date:  1992-09       Impact factor: 9.079

3.  Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study.

Authors:  L J van Doorn; Y Glupczynski; J G Kusters; F Mégraud; P Midolo; N Maggi-Solcà; D M Queiroz; N Nouhan; E Stet; W G Quint
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

4.  Indicator medium for isolation of Campylobacter pylori.

Authors:  D M Queiroz; E N Mendes; G A Rocha
Journal:  J Clin Microbiol       Date:  1987-12       Impact factor: 5.948

5.  A 9 year study of clarithromycin and metronidazole resistance in Helicobacter pylori from Spanish children.

Authors:  M López-Brea; M J Martínez; D Domingo; T Alarcón
Journal:  J Antimicrob Chemother       Date:  2001-08       Impact factor: 5.790

6.  Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico.

Authors:  J Torres; M Camorlinga-Ponce; G Pérez-Pérez; A Madrazo-De la Garza; M Dehesa; G González-Valencia; O Muñoz
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

7.  Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil.

Authors:  S Mendonça; C Ecclissato; M S Sartori; A P Godoy; R A Guerzoni; M Degger; J Pedrazzoli
Journal:  Helicobacter       Date:  2000-06       Impact factor: 5.753

8.  Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. pylori RdxA(+) (Nitroreductase) gene.

Authors:  G Sisson; J Y Jeong; A Goodwin; L Bryden; N Rossler; S Lim-Morrison; A Raudonikiene; D E Berg; P S Hoffman
Journal:  J Bacteriol       Date:  2000-09       Impact factor: 3.490

9.  Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori.

Authors:  G Wang; M S Rahman; M Z Humayun; D E Taylor
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

10.  Metronidazole and clarithromycin susceptibility and the subtypes of vacA of Helicobacter pylori isolates in Estonia.

Authors:  K Lõivukene; H Kolk; H I Maaroos; P Kasenõmm; M Ustav; M Mikelsaar
Journal:  Scand J Infect Dis       Date:  2000
View more
  18 in total

Review 1.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer.

Authors:  Maria Aparecida Mesquita; Sonia Letícia Silva Lorena; Jazon Romilson Souza Almeida; Ciro Garcia Montes; Fábio Guerrazzi; Luciana T Campos; José Murilo Rubiota Zeitune
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

3.  Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium.

Authors:  V Y Miendje Deyi; V Y Miendje Deyi; P Bontems; J Vanderpas; E De Koster; R Ntounda; C Van den Borre; S Cadranel; A Burette
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

4.  Trends in secondary antibiotic resistance of Helicobacter pylori from 2007 to 2014: has the tide turned?

Authors:  Doron Boltin; Haim Ben-Zvi; Tsachi Tsadok Perets; Zvi Kamenetsky; Zmira Samra; Ram Dickman; Yaron Niv
Journal:  J Clin Microbiol       Date:  2014-11-26       Impact factor: 5.948

5.  High prevalence of clarithromycin resistance and cagA, vacA, iceA2, and babA2 genotypes of Helicobacter pylori in Brazilian children.

Authors:  Gabriella T Garcia; Katia R S Aranda; Manoel E P Gonçalves; Silvia R Cardoso; Kiyoshi Iriya; Neusa P Silva; Isabel C A Scaletsky
Journal:  J Clin Microbiol       Date:  2010-09-08       Impact factor: 5.948

6.  Clinical relevance of the cagA and vacA s1m1 status and antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis.

Authors:  Mohsen Karbalaei; Amin Talebi Bezmin Abadi; Masoud Keikha
Journal:  BMC Infect Dis       Date:  2022-06-25       Impact factor: 3.667

Review 7.  Fluoroquinolone-based protocols for eradication of Helicobacter pylori.

Authors:  Antonio Rispo; Pietro Capone; Fabiana Castiglione; Luigi Pasquale; Matilde Rea; Nicola Caporaso
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

8.  Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.

Authors:  Tomás Navarro-Rodriguez; Fernando Marcuz Silva; Ricardo Correa Barbuti; Rejane Mattar; Joaquim Prado Moraes-Filho; Maricê Nogueira de Oliveira; Cristina S Bogsan; Décio Chinzon; Jaime Natan Eisig
Journal:  BMC Gastroenterol       Date:  2013-03-26       Impact factor: 3.067

9.  Susceptibility-guided vs. empiric retreatment of Helicobacter pylori infection after treatment failure.

Authors:  Jacob Yahav; Zmira Samra; Yaron Niv; Charlesnika T Evans; Douglas J Passaro; Gabriel Dinari; Haim Shmuely
Journal:  Dig Dis Sci       Date:  2006-11-01       Impact factor: 3.487

10.  Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication.

Authors:  Jaime N Eisig; Fernando M Silva; Ricardo C Barbuti; Tomás Navarro Rodriguez; Peter Malfertheiner; Joaquim P P Moraes Filho; Schlioma Zaterka
Journal:  BMC Gastroenterol       Date:  2009-05-26       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.